Dr. Nebhan on the Efficacy of Checkpoint Inhibitors in Older Patients With Cancer

Video

Caroline Nebhan, MD, PhD, discusses the efficacy of checkpoint inhibitors in older patients with cancer.

Caroline Nebhan, MD, PhD, clinical fellow, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, discusses the efficacy of checkpoint inhibitors in older patients with cancer.

During the 2021 SITC Annual Meeting, findings from a multicenter, international cohort study evaluating the efficacy and toxicity of single-agent checkpoint inhibitors in patients with cancer aged 80 years or older were presented in a virtual poster.

The efficacy analysis evaluated patients with the 3 most common tumor types represented in the study: non–small cell lung cancer (NSCLC), melanoma, and genitourinary (GU) tumors, Nebhan says. The results of the study demonstrated that the objective response rate was 32.2% in patients with NSCLC, 39.3% in patients with melanoma, and 26.2% in patients with GU tumors. The median progression-free survival was 6.7 months, 11.1 months, and 6 months, respectively.

Ultimately, these findings demonstrated that older patients with NSCLC, melanoma, or GU tumors can derive a substantial response with single-agent checkpoint inhibitors, Nebhan concludes.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD